A real-world comparative analysis of cardiovascular (CV) safety and time to next treatment (TTNT) with acalabrutinib versus ibrutinib in treatment-naive patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).

Authors: Daniel Arthur Ermann, George Dranitsaris, Sibel Blau, Aaron Peevyhouse, Heather Neuhalfen, Svea K. Wahlstrom, Samantha L. Thompson, Anna Teschemaker, Vikram Shetty, Mayuer Narkhede

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.e23280

Source: Full article

---

Abstract

e23280